Canada Neurology Devices Market Analysis

Canada Neurology Device Market Executive Summary

Neurology devices are widely available in Canada and are regulated by Health Canada. Imaging devices, electroencephalographs (EEGs), deep brain stimulators (DBS), and spinal cord stimulators are among the devices used to diagnose and treat neurology conditions (SCS). The availability of these devices varies depending on the region and the device in question. The availability of these devices is generally determined by factors such as the patient's condition, a physician's recommendation, and the availability of funding from government or private insurance. Neuro-intervention procedures are minimally invasive treatments for head, neck, brain, and spine conditions. Rather than opening the skull or exposing the spinal column, a catheter can be inserted through a small incision (1.25-2 mm) in the major arteries of the peripheral body parts. This catheter can reach lesions along blood vessels and the most advanced devices, such as aspiration catheters, cerebral coils, and so on, are used in treatment in conjunction with image-guided techniques. The neuro intervention procedure has more advantages than traditional surgeries, such as less patient discomfort, less bleeding, and faster recovery and recently gained a lot of traction due to the high morbidity of neurology conditions in Canada. It's estimated 3.6 Mn Canadians have some kind of neurology condition and 1.5 Mn suffer qualitatively loss of life years due to a brain injury. While we have medications to help such people, the emerging field of electroceuticals may offer even more hope.

For decades, Canada has been a world leader in neuromodulation devices, pioneering studies in deep brain stimulation. With a long history of conducting clinical trials, and now moving on to the development of new devices, surgical epilepsy advancements have been outstanding. Canada has established the Center for Advancing Neurotechnology Innovation to Application (CRANIA), which will be run in collaboration with Krembil and will be specially equipped to perform neuromodulation surgery. This treatment, known as deep brain stimulation, has enabled neuromodulation devices that interface with the nervous system to change the brain, spinal cord, or nerve function.

The Canada Neurology Device Market is expected to be worth $1.01 billion in 2022 and $1.84 billion in 2030, with a CAGR of 7.8% during the forecast period. Brain surgery can be used to treat epilepsy by removing or altering parts of the brain to reduce or eliminate seizures. Creating a less invasive approach by implanting a neural interface processor (NURIP), which is a computer chip that detects when a seizure is about to occur and then delivers stimulation to stop it. The chip uses artificial intelligence, so the system learns over time when and where seizures occur in the brain and how to best stop them. New vagus nerve stimulation devices An implant in the chest sends electrical pulses to the brain via the vagus nerve in the neck, and it is already being used to reduce the number and duration of epilepsy seizures, but it may also help with other immunology conditions. Some neurostimulation, such as functional electrical stimulation, occurs on a short-term basis. This therapy is used after a stroke to deliver electrical shocks to a patient's affected muscles, making them more receptive to rehabilitation therapy. The C-arm can be imaged using Alpha CT to produce CT-like 3D data. Superimpose this 3D data or previous CT/MR data on the live display to more confidently guide device placement.

Market Dynamics

Market Growth Drivers

Neurology disorders are among the leading causes of disability in the Canadian population, and they impose a significant public health burden. An ageing Canadian population has resulted from increased life expectancy and a declining birth rate, and the proportion of age-adjusted mortality due to noncommunicable diseases has been steadily increasing. These diseases are frequently associated with chronic disability and a growing burden of care for patients, their families, and carers. The majority of neurology disease is caused by Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), brain tumours (BT), cerebral palsy (CP), dystonia, epilepsy, Huntington's disease (HD), hydrocephalus, multiple sclerosis (MS), muscular dystrophies (MD), neurotrauma, Parkinson's disease (PD), spina bifida (SB), and Tourette's syndrome (TS). As the population ages, this trend is highlighted in greater detail for Alzheimer's and Parkinson's disease because the incidence of these two common neurology diseases rises significantly after the age of 65.

Market Restraints

Some neurology devices can be expensive, and patients may have limited access to them due to financial constraints or limited reimbursement from public or private health insurance plans. The availability of certain neurology devices can be limited in certain parts of Canada, especially in rural or remote areas. The regulatory approval process for new or innovative neurology devices can be lengthy and complex, which may limit the availability of new devices in the Canadian market. Reimbursement policies for neurology devices can vary between provinces and territories in Canada, and some patients may not be able to access devices that are not covered by their health insurance plans. Patients with private health insurance plans may face restrictions or limitations on the devices covered by their plans, which can impact access to certain neurology devices. Some patients may not be aware of the available treatments for neurology conditions, and healthcare professionals may not be familiar with the latest devices and treatments. Canada has strict regulatory requirements for medical devices, which may limit the availability of some devices in the market.

Competitive Landscape

Key Players

• Medtronic
• Stryker
• Boston Scientific
• Johnson & Johnson
• Abbott Laboratories
• B Braun
• Penumbra Inc.
• Integra LifeSciences
• Smith & Nephew
• Terumo Medical Corporation

Notable Recent Deals

September 2022 - HealthTech Connex's NeuroCatch Platform 2.0 brain function assessment technology has been granted a medical device licence by Health Canada. NeuroCatch is a medical device that provides a rapid, objective assessment of cognitive brain function in minutes at the point of care. The technology is used to assess concussions and other neurology conditions in Canada and the United States. When monitoring neurology conditions such as concussions and brain injuries, the latest innovative advancements in the next-generation NeuroCatch enable 10-15 times improved sensitivity in detecting subtle but significant changes in brain function.

Healthcare Policies and Regulatory Landscape

The regulatory body for medical devices in Canada is Health Canada. The roles and responsibilities of Health Canada, the regulatory body for medical devices in Canada, include - Evaluating the safety, efficacy, and quality of medical devices before they are authorized for sale in Canada and establishing standards and guidelines for medical devices. It also monitors and inspects medical device manufacturing facilities, responds to adverse events and product recalls related to medical devices, provides information and guidance to industry and healthcare professionals, collaborates with international regulatory agencies to ensure that Canadian and international standards are aligned, regulates the labelling, advertising, and promotion of medical devices. The main goal of Health Canada is to protect and promote the health and safety of people by ensuring that medical devices available on the Canadian market are of high quality, safe, and effective.

Reimbursement Scenario

In Canada, medical devices such as neurology devices may be reimbursed through public or private health insurance plans. Reimbursement for medical devices can vary depending on the province or territory in which the patient resides, the specific device being used, and the individual patient's insurance coverage. The Canada Health Act outlines the principles that must be followed by provinces and territories when they provide funding for health services, but it is up to each province and territory to determine the specific medical services and devices that are covered under their respective health insurance plans. Some provinces and territories may provide full or partial reimbursement for certain medical devices, while others may not cover certain devices at all. Patients should consult their health insurance provider or the relevant government agency in their province or territory to determine the extent to which their medical devices are reimbursed.